157 related articles for article (PubMed ID: 32871938)
1. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
[TBL] [Abstract][Full Text] [Related]
2. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
3. A novel HNF1B mutation p.R177Q in autosomal dominant tubulointerstitial kidney disease and maturity-onset diabetes of the young type 5: A pedigree-based case report.
Tao T; Yang Y; Hu Z
Medicine (Baltimore); 2020 Jul; 99(31):e21438. PubMed ID: 32756155
[TBL] [Abstract][Full Text] [Related]
4. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy.
Docena MK; Faiman C; Stanley CM; Pantalone KM
Endocr Pract; 2014 Feb; 20(2):107-11. PubMed ID: 24014008
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
7. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.
Almutair A; Almulhem B
Front Endocrinol (Lausanne); 2024; 15():1294264. PubMed ID: 38524636
[TBL] [Abstract][Full Text] [Related]
9. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
Zaitoon H; Lubetzky R; Amir AZ; Moran-Lev H; Sagi L; Yacobi-Bach M; Borger O; Chorna E; Lebenthal Y; Brener A
Acta Diabetol; 2023 Aug; 60(8):1099-1108. PubMed ID: 37160786
[TBL] [Abstract][Full Text] [Related]
11. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.
Evans B; Stoltzfus B; Acharya N; Nyland JE; Arnold AC; Freet CS; Bunce SC; Grigson PS
Brain Res Bull; 2022 Oct; 189():163-173. PubMed ID: 36038016
[TBL] [Abstract][Full Text] [Related]
12. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
13. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
Kobori T; Onishi Y; Yoshida Y; Tahara T; Kikuchi T; Kubota T; Iwamoto M; Sawada T; Kobayashi R; Fujiwara H; Kasuga M
J Diabetes Investig; 2023 Jun; 14(6):767-773. PubMed ID: 36919944
[TBL] [Abstract][Full Text] [Related]
14. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
Bacha F
Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
[No Abstract] [Full Text] [Related]
15. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
von Scholten BJ; Hansen TW; Goetze JP; Persson F; Rossing P
J Diabetes Complications; 2015 Jul; 29(5):670-4. PubMed ID: 25935863
[TBL] [Abstract][Full Text] [Related]
17. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Baron HL
J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
19. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
20. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
